Danazol: an antigonadotrophic agent in the treatment of recurrent pelvic and intestinal endometriosis.
Six cases of pelvic endometriosis were treated with Danazol 400 mg daily for six months. In four of these cases, intestinal endometriosis of varying severity was also present. The initial results were very satisfactory except in one case with adenomyosis and continuous spotting. Follow-up after cessation of treatment suggests that in some cases a further period of treatment will be necessary.
D000284:Administration, Oral; D000328:Adult; D003613:Danazol / Q000008:administration & dosage / Q000627:therapeutic use*; D004341:Drug Evaluation; D004715:Endometriosis / Q000188:drug therapy* / Q000473:pathology; D004717:Endometrium / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007414:Intestinal Neoplasms / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local; D010386:Pelvic Neoplasms / Q000188:drug therapy*; D011245:Pregnadienes / Q000627:therapeutic use*; D011379:Prognosis
D011245:Pregnadienes; D003613:Danazol